Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: The outcome of incomplete resections
Introduction
Malignant pleural mesothelioma (MPM) is a rapidly fatal malignant disease originating from the mesothelial surfaces of the pleura. Macroscopic complete resection (MCR) is the goal of surgery and seems to have the most significant effect on survival in patients undergoing multimodality treatment for MPM [1]. However, the type of surgery for MPM depends not only on patients’ cardio-pulmonary reserves, disease distribution and histology of the disease, but also on surgeons’ preference and philosophy.
Either surgery in terms of extrapleural pneumonectomy (EPP), lung-sparing radical pleurectomy (RP), pleurectomy/decortication (PD) or extended pleurectomy/decortication (EPD) might achieve MCR. Despite that, it is unclear, if patients undergoing incomplete RP (R2) within a standardized multimodality treatment protocols have any advantage in terms of survival and if EPP should be carried out in these cases to avoid R2.
There is a lack of data with regard to lung-sparing RP for MPM intended to achieve MCR but resulted in R2. Thus, the present study intends to analyze R2 in patients undergoing RP for MPM as a prognosticator on overall survival.
Section snippets
Methods
All consecutive patients with diagnosis of MPM were evaluated prospectively for trimodality therapy with curative intent between 2002 and 2011 as reported previously [2]. The study (ClinicalTrials.gov identifier NCT01343264) was approved by the institutional review board. Written consent was obtained from each study patient. The study was conducted according to the revised Declaration of Helsinki and the requirements of good clinical practice. Macroscopic complete resections (MCR group) were
Patient characteristics
Eighty-eight out of 206 consecutive patients with histological confirmed diagnosis of MPM were included in the study and underwent RP. Surgical morbidity and mortality were 27.3% (24/88) and 2.3% (2/88), respectively. The most common complications were pneumonia (6/88, 6.8%), prolonged air leak (5/88, 5.7%) and atrial fibrillation (4/88, 4.5%), respectively. Neutropenic fever and sepsis during chemotherapy caused another death. Thus, the treatment related mortality from any cause was 3.4%
Discussion
In this retrospective analysis of a prospective evaluated standardized trimodality therapy concept including RP upfront followed by adjuvant cisplatin/pemetrexed and radiotherapy, we found out that R2 were associated with inferior outcomes and only very selected cases would have qualified for EPP to achieve MCR. R2 was correlated to advanced p-T-Status, p-N-Status and p-IMIG stage.
All surgical efforts focus on achieving MCR. It is not our philosophy that all patients benefit from surgery. This
Conclusions
R2 in patients undergoing RP are associated with inferior outcomes. The present results might help to identify a high-risk group of patients undergoing R2 and futile surgery. Only very selected cases (less than 4% in this series) would have qualified for EPP to achieve MCR. EPP might be an important surgical extension in selected patients to achieve MCR. There is a need for further investigation of effective intrapleural additive treatment options for patients undergoing incomplete resections.
Conflict of interest statement
None declared.
References (28)
Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma
J Thorac Oncol
(2006)- et al.
Trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy
Lung Cancer
(2011) - et al.
Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group
J Thorac Oncol
(2011) - et al.
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma
J Thorac Cardiovasc Surg
(2007) - et al.
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
Ann Oncol
(2007) - et al.
Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma
J Thorac Oncol
(2012) - et al.
Initial analysis of the international association for the study of lung cancer mesothelioma database
J Thorac Oncol
(2012) - et al.
Integrated computed tomography positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications
J Thorac Cardiovasc Surg
(2005) - et al.
Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma
Ann Thorac Surg
(2009) - et al.
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system
J Thorac Cardiovasc Surg
(2008)